COMMUNIQUÉS West-GlobeNewswire

Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
11/09/2017
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
EDAP Announces Filing of New 510(k) Application for Focal One® Device
11/09/2017
510(k) Includes New Clinical Data to Support EDAP's File LYON, France, September 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, today announced that the Company submitted a new 510(k [...]
Genedrive® HCV ID Kit received CE-IVD Certification
11/09/2017
11 September 2017 genedrive plc ("genedrive" or the "Company") Genedrive® HCV ID Kit received CE-IVD Certification Hepatitis C assay provides decentralised molecular testing to support the identification of patients [...]
Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market
11/09/2017
SAN DIEGO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has entered into [...]
ObsEva SA Announces Presentation Related to its PGF2alpha Receptor Antagonist at ACCP 2017 Annual Meeting
11/09/2017
Phase 1 clinical trial results in healthy subjects support cardiac safety of OBE022 Geneva, Switzerland and Boston, MA - 11 September, 2017 - ObsEva SA (NASDAQ: OBSV), a Swiss biopharmaceutical company focused on the [...]
Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces HAE Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial
11/09/2017
Shire's Investigational Subcutaneous C1 esterase inhibitor (C1 INH [Human]) Liquid for Injection (SHP616) Significantly Reduces Hereditary Angioedema Monthly Attack Rate Versus Placebo in a Phase 3 Pivotal Trial Median [...]
Summit Therapeutics Awarded BARDA Contract Worth Up To $62M To Support Development of Ridinilazole for CDI
11/09/2017
Summit Therapeutics plc ('Summit Therapeutics', Summit', or the 'Company') SUMMIT AWARDED BARDA CONTRACT WORTH UP TO $62 MILLION TO SUPPORT THE DEVELOPMENT OF RIDINILAZOLE FOR THE TREATMENT OF C. DIFFICILE INFECTION [...]
Shire plc : Elections for the interim dividend in respect of the six months to June 30, 2017
11/09/2017
Elections for the interim dividend in respect of the six months to June 30, 2017 September 11, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announced on August 3, 2017, an interim dividend of 5.09 US cents [...]
Medtronic Announces Voluntary Recall of Diabetes Infusion Sets
11/09/2017
DUBLIN - September 11, 2017 - Medtronic plc (NYSE:MDT) announced today that it has started to inform patients worldwide of a voluntary recall of specific lots of infusion sets used with all models of Medtronic insulin [...]
Novo Nordisk A/S - Share repurchase programme
11/09/2017
Bagsværd, Denmark, 11 September 2017 - On 2 February 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Symphogen A/S: Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress
11/09/2017
Symphogen presents detailed results for randomized Phase 2 study with Sym004 in refractory metastatic colorectal cancer at ESMO 2017 Congress Data show clinically meaningful improvement in overall survival in a [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Août 2017
11/09/2017
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights as of August 2017, 31.
11/09/2017
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote au 31 Juillet 2017
11/09/2017
DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]
Virbac : Declaration of the number of shares and voting rights as of July 2017, 31.
11/09/2017
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Principal Investigator Dr. James Gulley to Provide Presentation Entitled "Therapeutic Vaccines in Prostate Cancer" at the ESMO 2017 Congress
11/09/2017
MADRID, September 11, 2017 - This morning at the European Society for Medical Oncology (ESMO) 2017 Congress, Dr. James Gulley, Chief, Genitourinary Malignancies Branch, Senior Investigator, Head, Immunotherapy Section, [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
11/09/2017
FIT Biotech Oy Company release September 11, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Solon Eiendom ASA : Primary insider notification
11/09/2017
(Oslo, Norway, 08 September 2017) Solon Eiendom ASA Chairman of the Board Simen Thorsen (through his wholly owned company Hortulan AS) has today bought 133,553 shares in Solon Eiendom ASA at a price of NOK 17.5373 per [...]
Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold
11/09/2017
Press release 2017-09-11 Xbrane has confirmed an additional order of Spherotide from Pooyesh Darou, its partner in the Middle East, to a value of SEK 8.5 million to be delivered in Q4 2017. With this delivery Xbrane [...]

Pages